{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:23:25Z","timestamp":1781886205998,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"suppl_3","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI119954"],"award-info":[{"award-number":["U01AI119954"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Baylor Research Institute"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust, UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,28]]},"DOI":"10.1093\/cid\/ciy611","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T03:41:13Z","timestamp":1532662873000},"page":"S293-S302","source":"Crossref","is-referenced-by-count":90,"title":["Levofloxacin Pharmacokinetics\/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis"],"prefix":"10.1093","volume":"67","author":[{"given":"Devyani","family":"Deshpande","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotam G","family":"Pasipanodya","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellah G","family":"Mpagama","sequence":"additional","affiliation":[{"name":"Kibong\u2019oto Infectious Diseases Hospital, Sanya Juu, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Bendet","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thearith","family":"Koeuth","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooi S","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata M","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Thwaites","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, Churchill Hospital, Oxford, United Kingdom"},{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K","family":"Heysell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, University of Virginia, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8012","authenticated-orcid":false,"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"key\n\t\t\t\t2019012511194429000_CIT0001","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0002","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1086\/499046","article-title":"The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations","volume":"42","author":"Drusano","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.vascn.2010.01.006","article-title":"Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study","volume":"61","author":"Komatsu","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0004","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0005","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/AAC.49.8.3178-3181.2005","article-title":"Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance","volume":"49","author":"Gumbo","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0006","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0007","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.00379-15","article-title":"Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis","volume":"59","author":"Kempker","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0008","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/INF.0000000000001022","article-title":"Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands","volume":"35","author":"Mase","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0009","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0010","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1164\/rccm.201212-2328OC","article-title":"Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis","volume":"188","author":"Ahmad","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0012","doi-asserted-by":"crossref","first-page":"e0170663","DOI":"10.1371\/journal.pone.0170663","article-title":"Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania","volume":"12","author":"Ebers","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0013","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"key\n\t\t\t\t2019012511194429000_CIT0014","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Gatifloxacin pharmacokinetics\/pharmacodynamics-based optimal dosing for pulmonary and meningeal multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/cid\/ciw482","article-title":"Linezolid for infants and toddlers with disseminated tuberculosis: first steps","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1126\/sciadv.1701102","article-title":"Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis","volume":"3","author":"Deshpande","year":"2017","journal-title":"Sci Adv"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0017","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1093\/infdis\/jiv183","article-title":"Nonclinical models for antituberculosis drug development: a landscape analysis","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0018","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0019","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"key\n\t\t\t\t2019012511194429000_CIT0020","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1093\/cid\/ciy608","article-title":"An introduction to pharmacokinetics\/pharmacodynamics methods and scientific evidence base for dosing of second line tuberculosis drugs","volume":"67","author":"Gumbo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0021","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijantimicag.2006.03.022","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects","volume":"28","author":"Conte","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0022","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the milky way","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0023","doi-asserted-by":"crossref","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0024","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"D\u2019Argenio","year":"2009"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0026","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1128\/AAC.42.5.1098","article-title":"Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection","volume":"42","author":"Preston","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0027","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.46.2.586-589.2002","article-title":"Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation","volume":"46","author":"Drusano","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0028","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.47.10.3104-3108.2003","article-title":"Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy","volume":"47","author":"Pea","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0029","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis","volume":"20","author":"Rodr\u00edguez","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0030","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.5588\/ijtld.14.0277","article-title":"Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations","volume":"19","author":"Kambli","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0031","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0032","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0033","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Machine Learning"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0034","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","author":"Maruri","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity","volume":"48","author":"Aubry","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0036","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0037","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5588\/ijtld.15.0884","article-title":"Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis","volume":"20","author":"Chiang","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0038","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/civ427","article-title":"Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0039","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0040","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/civ425","article-title":"Systematic analysis of hollow fiber model of tuberculosis experiments","volume":"61","author":"Pasipanodya","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0041","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0042","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1128\/AAC.03549-14","article-title":"Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy","volume":"58","author":"Gumbo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0043","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0044","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3201\/eid2106.141873","article-title":"Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis","volume":"21","author":"Kempker","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0045","doi-asserted-by":"crossref","first-page":"e0176522","DOI":"10.1371\/journal.pone.0176522","article-title":"Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis","volume":"12","author":"Operario","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0046","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","author":"Schmalstieg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0047","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/ng.2675","article-title":"Biological variability and the emergence of multidrug-resistant tuberculosis","volume":"45","author":"Gumbo","year":"2013","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0048","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0049","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ910","article-title":"Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance","volume":"62","author":"Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019012511194429000_CIT0050","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy346","article-title":"Intermediate susceptibility dose-dependent breakpoints for high dose rifampicin, isoniazid and pyrazinamide treatment in multidrug-resistant tuberculosis programmes","author":"Zuur","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/suppl_3\/S293\/26826604\/ciy611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T02:07:24Z","timestamp":1751767644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/suppl_3\/S293\/5212787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":50,"journal-issue":{"issue":"suppl_3","published-online":{"date-parts":[[2018,11,28]]},"published-print":{"date-parts":[[2018,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy611","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12,15]]},"published":{"date-parts":[[2018,11,28]]}}}